C4 Therapeutics is a clinical-stage biotechnology company specializing in targeted protein degradation. It develops a TORPEDO platform used to design molecular glues and heterobifunctional degraders. The company is engaged in the treatment of various cancer types, such as myeloma, lymphoma, and lung cancer.